Afipia clevelandensis Antibodies and Cross-Reactivity with Brucella spp. and Yersinia enterocolitica O:9

MICHEL DRANCOURT, PHILIPPE BROUQUI, AND DIDIER RAOUOLT*

Unité des Rickettsies, CNRS UPR-SS A 6020, Faculté de Médecine, Université de la Méditerranée, 13385 Marseille Cedex 05, France

Received 8 May 1997/Returned for modification 23 July 1997/Accepted 27 August 1997

**Afipia clevelandensis** is a recently described gram-negative bacterium whose potential pathogenic role in human disease is under investigation. Only one strain, from the pretibial lesion of a patient hospitalized with necrotizing pancreatitis for 5 months, has been isolated. Using an indirect immunofluorescence assay to detect anti-*Afipia clevelandensis* antibodies, we found a seroprevalence of 1.5% among 30,194 sera routinely submitted for laboratory diagnosis of rickettsial diseases. However, among the 52 patients who were clinically evaluable and who exhibited detectable antibodies against *Afipia clevelandensis*, 42% were eventually diagnosed as certainly or probably having brucellosis and 15% were eventually diagnosed as certainly or probably having *Yersinia enterocolitica* O:9 infection, which is the serotype most often encountered in Europe. Western immunoblotting and cross-adsorption tests showed that an 11.5-kDa proteinase K-labile band and a 21-kDa proteinase-stable band, presumably lipopolysaccharide, were responsible for cross-reactivity among *Afipia clevelandensis*, *Brucella abortus*, and *Y. enterocolitica* O:9. Other diagnoses included nosocomial infections and various community-acquired diseases for which the role of *Afipia clevelandensis* remains undefined. Physicians and clinical microbiologists should be aware of this cross-reactivity in future assessments of the role of *Afipia clevelandensis* in human pathology.

*Afipia clevelandensis* is a recently described gram-negative bacterium which includes *Afipia felis*, *Afipia broomeae*, *Afipia clevelandensis*, and three unnamed genospecies (8). This genus is part of the alpha 2-subgroup of the class *Proteobacteria*, and along with *Bartonella* species (22), it is closely related to the human pathogens *Brucella* species and *Ochrobactrum anthropi* (formerly CDC group Vd bacteria) (18).

The precise role of *Afipia* species in human pathology remains largely unknown due to their rare isolation. Although *A. felis* was proposed as a putative agent of cat scratch disease (15), *Bartonella henselae* is diagnosed in most cases. *A. felis* was isolated on axenic medium from the adenomalignies of 10 patients with confirmed cat scratch disease (15), and 14 isolates were obtained with cultured cell systems (7). One additional isolate from an Israeli patient has recently been obtained on axenic medium (16). *A. felis* DNA has seldom been detected in clinical specimens (5), including codetection with *B. henselae* DNA (2), and one study failed to detect *A. felis* DNA in the enlarged lymph nodes of European patients with cat scratch disease (6). Discrepant results regarding the detection of specific antibodies in the serum of patients with cat scratch disease (15, 23) and the absence of detection in cat, however, has led to questions concerning the precise role of this species in cat scratch disease, particularly as growing evidence has been obtained for the role of *B. henselae* in this pathology (3, 4, 6). Three strains of *A. broomeae* have been cultured from human sources, including one isolate from the sputum of a patient in New Zealand in 1981, one isolate from the bone marrow of an American woman, and one isolate from the synovial fluid of an American patient with a wrist abscess. Three other *Afipia* strains, designated genospecies 1, 2, and 3 and as yet unnamed, have been described. These three isolates were obtained from human pleural fluid in a fatal case of pulmonary obstruction in 1981 (genospecies 1), from the bronchial washing of an 80-year-old woman with pneumonia (genospecies 2), and from water (genospecies 3). Only one strain of *Afipia clevelandensis* has been isolated to date and that was from a pretibial area biopsy in a 69-year-old American male patient hospitalized for 5 months with necrotizing pancreatitis who developed petechial lesions and erythematous plaques of the lower extremities (17). The timing of isolation indicated that this isolate was of nosocomial origin, and this strain was first related to other *Afipia* species on the basis of its unusual cellular fatty composition, characterized by 11-methyloctadec-12-enoic acid (20). Its precise pathogenic role in human beings remains unknown, particularly as no serology was performed in the unique patient with the *Afipia clevelandensis* isolate.

While investigating the potential role of this bacterium in human diseases, we prospectively tested the human sera sent to our laboratory for the presumptive diagnosis of rickettsiosis for the presence of anti-*Afipia clevelandensis* antibodies. We encountered a significant number of patients with confirmed brucellosis or *Yersinia enterocolitica* O:9 infection who demonstrated positive serology for *Afipia clevelandensis*. This observation led us to study the possibility of cross-reactivity among *Afipia clevelandensis*, *Brucella abortus*, and *Y. enterocolitica* O:9, and the results of this study are presented herein.

**MATERIALS AND METHODS**

* Bacteria. *Afipia clevelandensis* (ATCC 49720T) was obtained from the American Type Culture Collection (Rockville, Md.) and was grown on 5% sheep blood agar at 30°C under ambient atmosphere. *B. abortus* was isolated in our laboratory from a patient with endocarditis and was grown on 5% sheep blood agar. *Y. enterocolitica* O:9 was obtained as a clinical isolate from a patient with enteritis and was grown on Trypticase-soy agar.

* Patients and sera. All the sera received by our laboratory between 1 January 1993 and 31 December 1996 were tested for the presence of antibodies against *Afipia clevelandensis*. These sera had been sent by clinical microbiology laboratories from all over France for serological diagnosis of a number of rickettsial and bacterial diseases including spotted fever group and typhus group rickettsiosis, Q
fever, cat scratch disease, and Bartonella species infection. For sera exhibiting an anti-A. clevelandensis immunoglobulin G (IgG) titer of ≥1:200 or an IgM titer of ≥1:100, the clinical history of the patient was reviewed for any previous diagnosis of infectious disease, in particular those demonstrated to have been caused by Brucella species. Serological tests for A. clevelandensis and Y. enterocolitica O:9 antibodies were performed on sera obtained from such patients. A patient was defined as suffering brucellosis when any febrile illness was associated with the isolation of Brucella species from any clinical specimen or with exposure to cattle and a standard tube agglutination (STA) test titer of ≥1:160. A patient was defined as suffering from yersiniosis when enteritis was associated with the isolation of Y. enterocolitica O:9 from stool. One hundred sera collected from 100 healthy blood donors in France were included in the study as a negative control group. A panel of 32 sera obtained from 22 patients suffering past or active brucellosis who had been the subjects of a previous study (unpublished data) were screened for the presence of anti-A. clevelandensis IgG and IgM antibodies and for the presence of anti-Y. enterocolitica antibodies by the tests described above.

Serological tests for B. abortus and Y. enterocolitica. Serological testing for Brucella was performed by using a commercial STA test (Brucelloslide-Test; Biomerieux, Marcy-l’Etoile, France) and by using a microimmunofluorescence test. The STA test uses heat- and 0.5% phenol-inactivated B. abortus 99 (Waybridge strain) as the antigen, and the agglutination tests were performed according to the instructions of the manufacturer. Any agglutination was read as a positive result. Microimmunofluorescence was performed according to standard procedures by using the same antigen as for the STA test. Serological testing for Y. enterocolitica O:9 was performed by using a commercial complement fixation test (Institut Virion SA, Zürich, Switzerland) according to the instructions of the manufacturer. Any titer of ≥1:160 was considered positive.

Microimmunofluorescence assay for A. clevelandensis. Bacterial colonies of A. clevelandensis were harvested and suspended in phosphate-buffered saline (PBS) to obtain a suspension of 1-mg/ml protein. Aliquots of this suspension were disposed onto the wells of microscope slides, air dried, and then fixed in cold acetone. The sera were diluted in PBS containing 3% nonfat dry milk. Initially, all sera were screened at a dilution of 1:25 and, with a goat anti-human globulin fluorescein conjugate (Biomerieux), diluted to 1:400. Sera reacting at a dilution of 1:25 were restested to determine their IgG and IgM titters. The determination of IgM titters was performed after removing IgG with the rheumatoid factor absorbent reagent (Behring AG, Marburg, Germany) by using a goat anti-human IgM fluorescein conjugate (Biomerieux) diluted to 1:200. Slides containing fixed antigen overlaid with dilutions of sera were incubated for 30 min at 37°C in a moist chamber. The slides were then washed three times, for 10 min each time, in PBS and air dried. A drop (10 μl) of conjugate, diluted in PBS–3% nonfat dry milk with 0.025% Evans blue was then added to each slide well, and slides were reincubated for 30 min at 37°C in a moist chamber. The slides were then washed once for 10 min in distilled water and air dried before being mounted with buffered glycerol (Fluoprep; Biomerieux). The slides were observed with an epifluorescent microscope with a 40× objective. Serum bled from a mouse 1 month after an intraperitoneal injection with a suspention of A. clevelandensis was used as a positive control. This serum was revealed with an anti-mouse globulin fluorescein conjugate (Immunotech, Marseille, France).

Western immunoblotting. Bacteria were suspended in sterile distilled water, and the bacterial concentration was adjusted to 2.5 mg/ml by spectrophotometric reading at 280 nm (Protein analysis program pack; Shimadzu, Kyoto, Japan). Antigens were then prepared following one of two protocols: (i) 1 volume of antigen was mixed with one-half volume of 2× Laemmli solubilizer (4% sodium dodecyl sulfate, 0.5% 2-mercaptoethanol, 0.5% bromophenol blue) and one-half volume of sterile distilled water and incubated at 56°C for 2 h; (ii) 1 volume of antigen was mixed with one-half volume of 2× Laemmli solubilizer and one-quarter volume of 20-mg/ml proteinase K (Boehringer Mannheim France SA, Meylan, France) and was incubated at 56°C for 1 h; an additional quarter-volume of proteinase K was then added, and the mixture was incubated at 56°C for 1 h. SDS-polyacrylamide gel electrophoresis was performed on 20 μl of each preparation by using a 12.5% acrylamide separating gel with a 4% stacking gel and the Mini-Protein II cell apparatus (Bio-Rad, Richmond, Calif.) at 100 V for 2 h. Low-range molecular weight standards (Bio-Rad) were used to estimate the molecular weight of the separated proteins. The gel was stained with Coomassie blue R-250 (Bio-Rad). For Western blot analysis, the polyacrylamide gel was prepared as described above and transferred to a nitrocellulose membrane in a transblot cell (Bio-Rad) at 50 V for 4 h in a cold chamber. The membrane was blocked with 5% nonfat dry milk in TBS (20 mM Tris-HCl [pH 7.5], 500 mM NaCl, 0.1% Merthiolate). Sera from three patients were tested, one from a patient with confirmed brucellosis (IgG, 1:100; IgM, 1:50), one from a patient with positive A. clevelandensis serology (IgG, 1:200, IgM, 1:25) without evidence of brucellosis or Y. enterocolitica infection. Each serum sample was diluted (1:50) in TBS containing 3% nonfat dry milk and incubated with the membrane overnight. After three washes in PBS, the membrane was incubated for 1 h in peroxidase-conjugated goat anti-human IgG, anti-human IgM, or anti-human IgA (Immunotech). Conjugated antibodies were diluted (1:2000) in 3% NFDM-TBS before use. The nitrocellulose membrane was washed again in 3% NFDM-TBS, and immunologic reactions were detected colorimetrically (0.015% 4-chloro-1-naphthol-0.015% hydrogen peroxide in 16.7% methanol in TBS). The blots were washed using the Image apparatus and the QGEL-1D program (Applepie, Ilkirch, France).

Antibody titers

<table>
<thead>
<tr>
<th>Antibody titer</th>
<th>Number of sera positive:</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgG</td>
<td>1:25</td>
</tr>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>1:50</td>
</tr>
<tr>
<td></td>
<td>149</td>
</tr>
<tr>
<td></td>
<td>1:100</td>
</tr>
<tr>
<td></td>
<td>89</td>
</tr>
<tr>
<td></td>
<td>1:200</td>
</tr>
<tr>
<td></td>
<td>46</td>
</tr>
<tr>
<td></td>
<td>1:400</td>
</tr>
<tr>
<td></td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>1:800</td>
</tr>
<tr>
<td></td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>1:1,600</td>
</tr>
<tr>
<td></td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>1:3,200</td>
</tr>
<tr>
<td></td>
<td>1</td>
</tr>
</tbody>
</table>

* Of the total number of samples tested, 29,838 had an antibody titer of 0 for IgG and 29,904 had antibody titer of 0 for IgM.

### RESULTS

Sera and clinical records. A total of 30,194 sera were received and prospectively tested for the presence of antibody against A. clevelandensis between 1 January 1993 and 31 December 1996. The distribution of the titers is reported in Table 1. A total of 458 serum samples exhibited an IgG or IgM titer of ≥1:25 (1.5%). Among these serum samples, 154 samples collected in 102 patients exhibited an IgG titer of ≥1:200 or an IgM titer of ≥1:100. Clinical data were not available for 50 of these patients. Review of the clinical records of the remaining 52 patients found 22 patients with a diagnosis of brucellosis, 9 patients with nosocomial infection, 8 patients with a diagnosis of Y. enterocolitica O:9 enteritis, 2 patients with cat scratch disease, and 11 patients with miscellaneous diagnoses. Of the 11 patients with miscellaneous diagnoses (8 females and 3 males, aged 29 to 66 years old), 2 patients presented with community-acquired pneumonia of unknown etiology, 2 patients presented with enlarged lymph nodes of unknown etiology (cat scratch disease was excluded in both by means of negative serology for B. henselae and A. felis, negative molecular detection of B. henselae, and histology incompatible with this diagnosis), and 2 patients presented with chronic diarrhea of unknown etiology (one of them had a previously diagnosed chronic monocytic leukemia and the other developed a 6-month neutropenia with marked monocytosis; diarrhea resolved after treatment with doxycycline in both patients). One patient presented with a community-acquired meningococcalitis with coma of unknown etiology. A 29-year-old Spanish woman presented with relapsing culture-negative endocarditis which occurred 5 years after the implantation of a prosthetic aortic valve. The endocarditis finally resolved after administration of ceftriaxone plus doxycycline, and although microbiological documentation failed, the serum samples exhibited a 1:40 titer against Brucella and a 1:100 IgM titer against A. clevelandensis. One patient presented with an A. clevelandensis IgG...
exhibited an anti-

A. clevelandensis

serologies of IgG 5

DNA in one case; these patients exhibited

A. clevelandensis

immunofluorescence assay) and the detection of

B. henselae

presence of anti-

sented with a diagnosis of cat scratch disease confirmed by the

case), and

Staphylococcus aureus

(one case),

Pseudomonas fluorescens

species (one

case), and Staphylococcus aureus (one case). Two patients pre-

sented with a diagnosis of cat scratch disease confirmed by the

presence of anti-B. henselae IgG of 1:400 (measured by micro-

immunofluorescence assay) and the detection of B. henselae DNA in one case; these patients exhibited A. clevelandensis serologies of IgG = 0 and IgM = 1:100 and IgG = 1:400 and IgM = 0, respectively.

Cross-reactivity by immunofluorescence techniques. No anti-
bodies against A. clevelandensis, Brucella or Y. enterocolitica O:9 were detected among the 100 sera collected in 100 healthy blood donors. A correlation between IgG titers against B. abortus and A. clevelandensis was found among 32 sera from patients with documented, past or active brucellosis (Table 2). Of five sera exhibiting an anti-Brucella IgG titer of <1:160, none exhibited an anti-A. clevelandensis titer of >1:160. Of 20 sera with anti-Brucella IgG titers of ≥1:640, however, 14 (70%) exhibited anti-A. clevelandensis titers of >1:100. Likewise, 11 of 23 sera with a positive STA test for Brucella and 1 of 9 sera with a negative STA test exhibited anti-A. clevelandensis IgM titers of >1:40.

Western immunoblotting. The results of Western immunoblotting studies are presented in Fig. 1. The serum of the patient with documented brucellosis reacted strongly with native

B. abortus antigen, including a proteinase K-labile band of 11.5-kDa molecular mass. The serum also reacted with the 11.5-kDa proteinase K-stable smear. The serum of the patient with documented Y. enterocolitica O:9 infection reacted strongly with homologous antigen, including the 11.5-kDa band. It reacted only with this proteinase K-labile, 11.5-kDa band in B. abortus antigen and with a few antigenic bands in A. clevelandensis antigen, including the 11.5-kDa, proteinase K-labile band and a faint, 21-kDa, proteinase K-stable band. The serum of the patient with positive A. clevelandensis serology but no documented infection reacted with several bands in A. clevelandensis antigen, including the 11.5-kDa, proteinase K-labile band and a 21-kDa, proteinase K-stable band. This serum only reacted with the 11.5-kDa, proteinase K-labile band in B. abortus antigen and with numerous bands in Y. enterocolitica O:9 antigen, including the 11.5-kDa, proteinase K-labile band.

Adsorption tests. As featured by the study design, adsorption tests resulted in the disappearance of homologous antibodies, regardless of the antigen tested. Adsorption tests with Brucella as the antigenic adsorbant did not modify the titer of antibody against Y. enterocolitica O:9 but led to a fourfold decrease in the anti-A. clevelandensis antibody titer. An ad-

![Image](http://cvi.asm.org/)
A. clevelandensis serology with homologous antigen altered the profiles of A. clevelandensis and B. abortus and suppressed reactivity against the 11.5-kDa band of Y. enterocolitica O:9.

DISCUSSION

Using a microimmunofluorescence assay, we prospectively tested 30,194 human serum samples collected over 48 months for the presence of antibodies to A. clevelandensis and correlated positive results with clinical presentation and diagnosis of the patients. During the course of this study, it appeared that among the 52 patients clinically evaluable and exhibiting detectable antibodies against A. clevelandensis, 42% were eventually diagnosed as certainly or probably having brucellosis and 15% were eventually diagnosed as certainly or probably having Y. enterocolitica O:9 infection, which is the serotype most often encountered in Europe (10). No isolation of A. clevelandensis was made among these patients. Considering the group of patients with certain and probable brucellosis or Y. enterocolitica infection, an IgM titer of 1:200 or more had a positive predictive value of 0.6 for brucellosis, an IgG titer of 1:400 or more had a positive predictive value for either brucellosis or Y. enterocolitica infection of 0.9, and a IgG titer of 1:800 or more had a positive predictive value for brucellosis of 0.84. Apart from patients with brucellosis or Yersinia infection, we observed 20 patients with significant levels of anti-A. clevelandensis antibodies who did not match the diagnostic criteria for brucellosis or yersiniosis. Pseudomonas species may account for some cross-reactivities in patients with nosocomial infection. Hall et al. reported the unique isolation of A. clevelandensis in an American patient after months of hospitalization and undescribed antibiotic treatments (17), supporting the conclusion that A. clevelandensis is thus capable of causing nosocomial infection. Antibiotic resistance reported for this species (8), presumably constitutive in the absence of detectable plasmid, is compatible with its selection either from the hospital environment or indigenous flora of this patient. Among patients with community-acquired diseases, one patient presented with necrotizing pancreatitis reminiscent of the patient who has yielded the only A. clevelandensis isolate. This patient in our study had elevated IgG and IgM titers at the time of admission, but as no microbiological documentation was performed the significance of this result is unclear. Only one serologic study of A. clevelandensis has been previously reported (21). In that study, which used a microagglutination test, 94 of 336 sera exhibited agglutination and 47 sera (14%) were considered positive (antibody titer of >20) by the authors. In the same study, the percent positivity for A. felis, A. broomae, and each of the three unnamed Afipia genospecies was 7, 3, and <=1 respectively. No correlation between positive serology and clinical disease was made. Using microimmunofluorescence, we found a lower seroprevalence of anti-A. clevelandensis antibodies, i.e., 1.5% (IgG or IgM titers of >=1:25). This discrepancy between the rates of seroprevalence may be due to differences in the number of sera included in these studies (336 versus 30,194) or to the serological techniques themselves (microagglutination versus microimmunofluorescence). Also, differences in seroprevalence in different geographic areas could be hypothesized since the prevalence of Yersinia infections is greater in northern Europe and that of brucellosis is greater in southern Europe. Both studies, however, confirm a significant seroprevalence against A. clevelandensis despite this species being represented by a sole isolate and having an unknown pathologic role in humans.

Our clinical observations led us to postulate a cross-reactivity among A. clevelandensis, B. abortus, and Y. enterocolitica.
O:9. Cross-reactivity has been previously reported between \textit{B. abortus} and other lipopolysaccharide-containing bacteria including \textit{Escherichia coli} O157 (13), \textit{Y. enterocolitica} O:9 (1), and \textit{O. anthropi} (24), as demonstrated by agglutination, complement fixation tests, immunoblotting, and delayed-type hypersensitivity tests. Interestingly, the genera \textit{Afipia}, \textit{Brucella}, and \textit{Ochrobactrum} all belong to the \(\alpha\) subdivision of the class \textit{Proteobacteria}. The smooth-type \textit{Brucella} species have been found to contain two distinct antigenic determinants designated A and M (14). Cross-reaction between the A lipopolysaccharide of \textit{Brucella} species and \textit{Y. enterocolitica} has been associated with the chemical similarity of the O-polysaccharide chains of the two species (9, 11, 12). The data presented herein confirm cross-reactivity between both bacterial species and show that a 21-kDa, proteinase K-stable antigen, presumably lipopolysaccharide, and an 11.5-kDa, proteinase K-labile antigen are responsible for the cross-reactivity among the three bacterial species. Interestingly, the 11.5-kDa protein is common to the three species.

In the search for the potential role of \textit{A. clevelandensis} in human diseases, bacteriologists and physicians must be aware of the cross-reactivity among this bacterium, \textit{Brucella} species, and \textit{Y. enterocolitica} and that no serological method can reliably distinguish between these pathogens. Further assessment of the role of \textit{A. clevelandensis} in human pathology must therefore aim for the isolation or direct characterization of the bacterium in clinical samples, particularly in patients with nosocomial infections.

**ACKNOWLEDGMENTS**

We acknowledge J. P. Tasei, who provided sera from patients with brucellosis, R. Birtles for reviewing the manuscript, and M. Enea for expert technical assistance.

This work was made possible thanks to Programme Hospitalier de Recherche Clinique, Assistance Publique à Marseille, 1993.

**REFERENCES**